Shanthi Marur1, Barbara Burtness. 1. aJohns Hopkins University, School of Medicine, Baltimore, Maryland bFox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Abstract
PURPOSE OF REVIEW: To discuss the changing landscape and significant developments in the diagnosis and management of oropharyngeal squamous cell carcinoma. RECENT FINDINGS: High-risk human papilloma viruses (HPVs) have been recognized as important causative factors for oropharyngeal cancer. The diagnosis is established with type-specific and broad-spectrum in-situ hybridization probes and/or p16 immunohistochemistry assays on fresh frozen paraffin-embedded tissue blocks. HPV-associated tumors have superior response and outcomes compared with HPV-unrelated tumors. Retrospective studies have been able to stratify oropharyngeal squamous cell carcinoma based on HPV status, tumor stage, nodal stage, and smoking history into risk groups with differing risks of death or distant disease. Selected patients, nonsmokers with less advanced nodal stage, may be overtreated with current treatment paradigms, and deintensification of curative therapy is a current research focus for these patients. Smokers, patients with advanced nodal or tumor stage, and those with HPV-unrelated cancers have a less favorable prognosis and the search for novel targets is particularly important for these patients. SUMMARY: The present review will highlight the current standards and the future direction of novel therapies in both HPV-associated and HPV-unrelated cancers.
PURPOSE OF REVIEW: To discuss the changing landscape and significant developments in the diagnosis and management of oropharyngeal squamous cell carcinoma. RECENT FINDINGS: High-risk human papilloma viruses (HPVs) have been recognized as important causative factors for oropharyngeal cancer. The diagnosis is established with type-specific and broad-spectrum in-situ hybridization probes and/or p16 immunohistochemistry assays on fresh frozen paraffin-embedded tissue blocks. HPV-associated tumors have superior response and outcomes compared with HPV-unrelated tumors. Retrospective studies have been able to stratify oropharyngeal squamous cell carcinoma based on HPV status, tumor stage, nodal stage, and smoking history into risk groups with differing risks of death or distant disease. Selected patients, nonsmokers with less advanced nodal stage, may be overtreated with current treatment paradigms, and deintensification of curative therapy is a current research focus for these patients. Smokers, patients with advanced nodal or tumor stage, and those with HPV-unrelated cancers have a less favorable prognosis and the search for novel targets is particularly important for these patients. SUMMARY: The present review will highlight the current standards and the future direction of novel therapies in both HPV-associated and HPV-unrelated cancers.
Authors: Daniel W Vermeer; William C Spanos; Paola D Vermeer; Annie M Bruns; Kimberly M Lee; John H Lee Journal: Int J Cancer Date: 2013-02-12 Impact factor: 7.396
Authors: Brian O'Sullivan; Shao Hui Huang; Lillian L Siu; John Waldron; Helen Zhao; Bayardo Perez-Ordonez; Ilan Weinreb; John Kim; Jolie Ringash; Andrew Bayley; Laura A Dawson; Andrew Hope; John Cho; Jonathan Irish; Ralph Gilbert; Patrick Gullane; Angela Hui; Fei-Fei Liu; Eric Chen; Wei Xu Journal: J Clin Oncol Date: 2013-01-07 Impact factor: 44.544
Authors: Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner Journal: Lancet Oncol Date: 2013-02-13 Impact factor: 41.316
Authors: Andrew G Schache; Triantafilos Liloglou; Janet M Risk; Anastasia Filia; Terence M Jones; Jon Sheard; Julia A Woolgar; Timothy R Helliwell; Asterios Triantafyllou; Max Robinson; Philip Sloan; Colin Harvey-Woodworth; Daniel Sisson; Richard J Shaw Journal: Clin Cancer Res Date: 2011-10-01 Impact factor: 12.531
Authors: George Kurdgelashvili; Graça M Dores; Samer A Srour; Anil K Chaturvedi; Mark M Huycke; Susan S Devesa Journal: Cancer Date: 2013-04-11 Impact factor: 6.860
Authors: Vivian W Y Lui; Matthew L Hedberg; Hua Li; Bhavana S Vangara; Kelsey Pendleton; Yan Zeng; Yiling Lu; Qiuhong Zhang; Yu Du; Breean R Gilbert; Maria Freilino; Sam Sauerwein; Noah D Peyser; Dong Xiao; Brenda Diergaarde; Lin Wang; Simion Chiosea; Raja Seethala; Jonas T Johnson; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris; Marjorie Romkes; Tomoko Nukui; Patrick Kwok-Shing Ng; Levi A Garraway; Peter S Hammerman; Gordon B Mills; Jennifer R Grandis Journal: Cancer Discov Date: 2013-04-25 Impact factor: 39.397
Authors: Richard C Jordan; Mark W Lingen; Bayardo Perez-Ordonez; Xin He; Robert Pickard; Michael Koluder; Bo Jiang; Paul Wakely; Weihong Xiao; Maura L Gillison Journal: Am J Surg Pathol Date: 2012-07 Impact factor: 6.394
Authors: Pawadee Lohavanichbutr; John Houck; Wenhong Fan; Bevan Yueh; Eduardo Mendez; Neal Futran; David R Doody; Melissa P Upton; D Gregory Farwell; Stephen M Schwartz; Lue Ping Zhao; Chu Chen Journal: Arch Otolaryngol Head Neck Surg Date: 2009-02
Authors: Antti Silvoniemi; Mueez U Din; Sami Suilamo; Tony Shepherd; Heikki Minn Journal: Int J Comput Assist Radiol Surg Date: 2016-01-25 Impact factor: 2.924
Authors: Elizabeth A Simonik; Ying Cai; Katherine N Kimmelshue; Dana M Brantley-Sieders; Holli A Loomans; Claudia D Andl; Grant M Westlake; Victoria M Youngblood; Jin Chen; Wendell G Yarbrough; Brandee T Brown; Lalitha Nagarajan; Stephen J Brandt Journal: PLoS One Date: 2016-10-25 Impact factor: 3.240
Authors: Piotr Kędzierawski; Anna Huruk-Kuchinka; Agnieszka Radowicz-Chil; Ryszard Mężyk; Zdzisława Rugała; Jacek Sadowski Journal: Arch Med Sci Date: 2020-09-23 Impact factor: 3.318
Authors: Tim N Beck; John Kaczmar; Elizabeth Handorf; Anna Nikonova; Cara Dubyk; Suraj Peri; Miriam Lango; John A Ridge; Ilya G Serebriiskii; Barbara Burtness; Erica A Golemis; Ranee Mehra Journal: Oncotarget Date: 2015-08-07